Fundraising FoxClene Nanomedicine
Salt Lake City, US · Delaware corporation · 1 known investors
Find your way into Clene Nanomedicine
Sign up to see every warm intro you have to Clene Nanomedicine
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Clene Nanomedicine team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
RE
Rob EtheringtonCEO/PresidentRob Etherington is Founding President and CEO of Clene Nanomedicine, a clinical-stage biopharmaceutical company developing CNM-Au8 for neurodegenerative diseases. He brings over 30 years of experience in biopharma drug development and executive roles at global pharmaceutical and biotech companies, and has led Clene through its 2021 Nasdaq public listing.
RL
Ryan LundNamed on SEC filing
JS
John StevensNamed on SEC filing
DL
David LisonbeeNamed on SEC filing
CY
Chad YoungNamed on SEC filing
RW
Reed WilcoxNamed on SEC filing
SJ
Shalom JacobovitzNamed on SEC filing
AM
Alison MoscaNamed on SEC filing
RG
Robert GayNamed on SEC filing
Investors · 1
Also in the syndicate · 1
SymBiosis II, LLClead
Reported raises · per SEC filings
Form D private placements$48.7M disclosed across 2 rounds · 2020
▶$42.5MraisedAug 2020 · 61 investors · PharmaceuticalsRule 506(b)
▶$42.5MraisedAug 2020 · 61 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shalom JacobovitzDirector
- Alison MoscaDirector
- Chad YoungDirector
- Reed WilcoxDirector
- David LisonbeeDirector
- John StevensDirector
- Robert GayDirector
- Rob EtheringtonExecutive Officer, Director
- Offering amount
- $46.2M
- Amount sold
- $42.5M
- Minimum investment
- $10K
- Sales commissions
- $949.1K
- Placement agents
- Crewe Capital, LLC
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.1MraisedJul 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$6.1MraisedJul 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ryan LundDirector
- John StevensDirector
- Rob EtheringtonExecutive Officer, Director
- David LisonbeeDirector
- Chad YoungDirector
- Reed WilcoxDirector
- Shalom JacobovitzDirector
- Alison MoscaDirector
- Robert GayDirector
- Offering amount
- $7M
- Amount sold
- $6.1M
- Minimum investment
- $25K
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Clene Nanomedicine raised?
- Clene Nanomedicine has disclosed $48.7M raised across 2 rounds.
- Where is Clene Nanomedicine headquartered?
- Clene Nanomedicine is headquartered in Salt Lake City, US.